ID

31537

Beskrivning

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00427999

Länk

https://clinicaltrials.gov/show/NCT00427999

Nyckelord

Versioner (1)
  1. 2018-09-03 2018-09-03 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

3 september 2018

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Prostate Cancer NCT00427999

Engelsk

Eligibility Prostate Cancer NCT00427999

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration).
Beskrivning

Prostate carcinoma | Disease Progression | Status post Hormone Therapy Primary | Male Castration | Medical Castration

Datatyp

boolean

Alias
UMLS CUI [1]
C0600139
UMLS CUI [2]
C0242656
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0279025
UMLS CUI [3,3]
C0205225
UMLS CUI [4]
C0007347
UMLS CUI [5]
C1513054
patients must have increasing psa levels (within 3 months prior to enrollment) with at least two consecutively increasing psa levels.
Beskrivning

Serum Prostate Specific Antigen Increased Measurement Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1883014
UMLS CUI [1,2]
C0242485
UMLS CUI [1,3]
C1265611
psa value before inclusion must be at least 5 ng/ml
Beskrivning

Prostate specific antigen measurement

Datatyp

boolean

Alias
UMLS CUI [1]
C0201544
at least 18 years of age.
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
at least capable of self care and up of at least 50% of waking hours (ecog performance status 0 - 2), adequate bone marrow function and lab results.
Beskrivning

Able to perform self care | Waking Hour Percentage | ECOG performance status | Bone Marrow function | Laboratory Results

Datatyp

boolean

Alias
UMLS CUI [1]
C2712073
UMLS CUI [2,1]
C0442696
UMLS CUI [2,2]
C0439227
UMLS CUI [2,3]
C0439165
UMLS CUI [3]
C1520224
UMLS CUI [4,1]
C0005953
UMLS CUI [4,2]
C0031843
UMLS CUI [5]
C1254595
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
change of hormone therapy within 6 weeks prior inclusion
Beskrivning

Hormone Therapy Change

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C0392747
prior chemotherapy
Beskrivning

Prior Chemotherapy

Datatyp

boolean

Alias
UMLS CUI [1]
C1514457
therapy with imatinib, or therapy with other inhibitors of tyrosinkinase.
Beskrivning

imatinib | Tyrosine kinase inhibitor

Datatyp

boolean

Alias
UMLS CUI [1]
C0935989
UMLS CUI [2]
C1268567
second neoplasm diagnosed within 5 years before study start.
Beskrivning

Second Cancer

Datatyp

boolean

Alias
UMLS CUI [1]
C0751623
patients who require therapy with warfarin
Beskrivning

Warfarin Required

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0043031
UMLS CUI [1,2]
C1514873
known diagnosis of hiv, hepatitis b, or hepatitis c infection.
Beskrivning

HIV Infection | Hepatitis B | Hepatitis C

Datatyp

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
Beskrivning

Disease Severe Interferes with Diagnosis | Disease Unstable Interferes with Diagnosis | Disease Uncontrolled Interferes with Diagnosis | Disease Severe Interferes with Evaluation | Disease Unstable Interferes with Evaluation | Disease Uncontrolled Interferes with Evaluation | Heart failure Severe

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C0011900
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0443343
UMLS CUI [2,3]
C0521102
UMLS CUI [2,4]
C0011900
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C0205318
UMLS CUI [3,3]
C0521102
UMLS CUI [3,4]
C0011900
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C0205082
UMLS CUI [4,3]
C0521102
UMLS CUI [4,4]
C1261322
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0443343
UMLS CUI [5,3]
C0521102
UMLS CUI [5,4]
C1261322
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C0205318
UMLS CUI [6,3]
C0521102
UMLS CUI [6,4]
C1261322
UMLS CUI [7,1]
C0018801
UMLS CUI [7,2]
C0205082
surgical therapy within 4 weeks before inclusion.
Beskrivning

Operative Surgical Procedures Recently

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0332185
prior therapy with isotopes strontium or rhenium.
Beskrivning

Strontium Isotopes | rhenium

Datatyp

boolean

Alias
UMLS CUI [1]
C0038468
UMLS CUI [2]
C0035419
radiation therapy to > 25% of bone marrow within 4 weeks before inclusion.
Beskrivning

Therapeutic radiology procedure Bone Marrow Percentage

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
treatment with other experimental substances within 30 days before study start.
Beskrivning

Experimental drug

Datatyp

boolean

Alias
UMLS CUI [1]
C0304229
other protocol-defined inclusion/exclusion criteria may apply
Beskrivning

Eligibility Criteria Study Protocol

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Tillbaka till toppen

Similar models

Eligibility Prostate Cancer NCT00427999

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Prostate carcinoma | Disease Progression | Status post Hormone Therapy Primary | Male Castration | Medical Castration
Item
histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration).
boolean
C0600139 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0279025 (UMLS CUI [3,2])
C0205225 (UMLS CUI [3,3])
C0007347 (UMLS CUI [4])
C1513054 (UMLS CUI [5])
Serum Prostate Specific Antigen Increased Measurement Quantity
Item
patients must have increasing psa levels (within 3 months prior to enrollment) with at least two consecutively increasing psa levels.
boolean
C1883014 (UMLS CUI [1,1])
C0242485 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Prostate specific antigen measurement
Item
psa value before inclusion must be at least 5 ng/ml
boolean
C0201544 (UMLS CUI [1])
Age
Item
at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Able to perform self care | Waking Hour Percentage | ECOG performance status | Bone Marrow function | Laboratory Results
Item
at least capable of self care and up of at least 50% of waking hours (ecog performance status 0 - 2), adequate bone marrow function and lab results.
boolean
C2712073 (UMLS CUI [1])
C0442696 (UMLS CUI [2,1])
C0439227 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
C1520224 (UMLS CUI [3])
C0005953 (UMLS CUI [4,1])
C0031843 (UMLS CUI [4,2])
C1254595 (UMLS CUI [5])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy Change
Item
change of hormone therapy within 6 weeks prior inclusion
boolean
C0279025 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
Prior Chemotherapy
Item
prior chemotherapy
boolean
C1514457 (UMLS CUI [1])
imatinib | Tyrosine kinase inhibitor
Item
therapy with imatinib, or therapy with other inhibitors of tyrosinkinase.
boolean
C0935989 (UMLS CUI [1])
C1268567 (UMLS CUI [2])
Second Cancer
Item
second neoplasm diagnosed within 5 years before study start.
boolean
C0751623 (UMLS CUI [1])
Warfarin Required
Item
patients who require therapy with warfarin
boolean
C0043031 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
HIV Infection | Hepatitis B | Hepatitis C
Item
known diagnosis of hiv, hepatitis b, or hepatitis c infection.
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Disease Severe Interferes with Diagnosis | Disease Unstable Interferes with Diagnosis | Disease Uncontrolled Interferes with Diagnosis | Disease Severe Interferes with Evaluation | Disease Unstable Interferes with Evaluation | Disease Uncontrolled Interferes with Evaluation | Heart failure Severe
Item
severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency
boolean
C0012634 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0011900 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0443343 (UMLS CUI [2,2])
C0521102 (UMLS CUI [2,3])
C0011900 (UMLS CUI [2,4])
C0012634 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0521102 (UMLS CUI [3,3])
C0011900 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0521102 (UMLS CUI [4,3])
C1261322 (UMLS CUI [4,4])
C0012634 (UMLS CUI [5,1])
C0443343 (UMLS CUI [5,2])
C0521102 (UMLS CUI [5,3])
C1261322 (UMLS CUI [5,4])
C0012634 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
C0521102 (UMLS CUI [6,3])
C1261322 (UMLS CUI [6,4])
C0018801 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
Operative Surgical Procedures Recently
Item
surgical therapy within 4 weeks before inclusion.
boolean
C0543467 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Strontium Isotopes | rhenium
Item
prior therapy with isotopes strontium or rhenium.
boolean
C0038468 (UMLS CUI [1])
C0035419 (UMLS CUI [2])
Therapeutic radiology procedure Bone Marrow Percentage
Item
radiation therapy to > 25% of bone marrow within 4 weeks before inclusion.
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Experimental drug
Item
treatment with other experimental substances within 30 days before study start.
boolean
C0304229 (UMLS CUI [1])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial